Medical experts have debunked widespread fears that hydroxyurea, a drug widely used in the management of sickle cell disorder, causes infertility in patients. The clarification was made during a recent medical forum where specialists in hematology and reproductive health jointly reviewed available scientific evidence, stressing that no credible research has established a direct link between hydroxyurea therapy and infertility among individuals living with the genetic condition.
According to the experts, hydroxyurea remains one of the most effective drugs for sickle cell management, as it helps reduce the frequency of painful crises, lowers the risk of organ damage, and improves overall quality of life for patients. They warned that misinformation around its use could discourage patients from adhering to prescribed treatment, which in turn may worsen health outcomes and increase mortality rates.
Hematologists explained that while fertility challenges have been observed in some sickle cell patients, such issues are often related to the disease itself rather than hydroxyurea treatment. They noted that sickle cell disorder can affect various organs, including those involved in reproduction, thereby complicating fertility. However, existing studies have shown no conclusive evidence that the drug independently impairs reproductive health.
Reproductive specialists at the forum added that couples with sickle cell disease who are on hydroxyurea have successfully conceived and delivered healthy children. They emphasized that with proper medical guidance and monitoring, the drug remains safe for long-term use, especially as part of comprehensive care designed to extend life expectancy and reduce complications.
The experts further called on healthcare providers to intensify patient education to counter myths and misconceptions surrounding hydroxyurea. They maintained that providing accurate information will empower patients to make informed decisions about their treatment, thereby reducing the risks associated with abandoning effective medication.
Civil society groups and advocacy organizations present at the forum also urged the government to make hydroxyurea more accessible and affordable for Nigerians living with sickle cell disease. They argued that wider access to the drug, coupled with public enlightenment, would significantly improve health outcomes for thousands of patients battling the condition nationwide.
As the global medical community continues to research sickle cell disease and its management, Nigerian experts reaffirmed that hydroxyurea remains a safe, reliable, and life-saving option. They insisted that its benefits far outweigh unfounded concerns, urging patients and families to trust medical advice rather than unverified claims.
